Biotricity shareholders reject proposal to issue $6.6M in common stock upon Series B conversion

BIOTRICITY INC.

Annual meeting held August 15, 2024; all four director nominees elected.
Ratification of SRCO Professional Corporation as independent auditor approved with 12.24M votes for.
Proposal to issue up to $6.6M in common stock upon Series B Preferred conversion rejected (1.4M for, 10.9M against).
Elected directors: Waqaas Al-Siddiq, David A. Rosa, Ronald McClurg, and Jainal Bhuiyan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.